0

Month: February 2016

ARB Azilsartan Shows Greater Efficacy in Lowering Blood Pressure Among Patients with Prediabetes and Type 2 Diabetes

ARB Azilsartan Shows Greater Efficacy in Lowering Blood Pressure Among Patients with Prediabetes and Type 2 Diabetes

Results of a recent analysis that compared the efficacy, safety, and metabolic effects of the angiotensin-receptor blocker (ARB) azilsartan medoxomil to valsartan and olmesartan separately in patients with prediabetes and type 2 diabetes found that azilsartan (80 mg) lowered systolic blood pressure to a significantly greater degree than either valsartan or olmesartan. Read more

Share onShare on FacebookShare on Google+Tweet about this on TwitterShare on LinkedInPin on PinterestShare on TumblrEmail this to someone

FH Foundation Initiative Helps “FIND FH”

Officially launched in January 2014 by the FH Foundation, FIND FH® is a specific data mining initiative that uses multiple types of healthcare datasets to identify probable individuals with familial hypercholesterolemia, or FH, and provides a resource for healthcare professionals to encourage screening.

The initiative consists of three elements, the first of which is a lab and claims algorithm based on a database that the FH Foundation developed of more than 89 million Americans with cardiovascular disease. An EHR (electronic health records) algorithm and HCP/individual engagement comprise the second and third elements of the FIND FH® initiative, respectively. Read more

Share onShare on FacebookShare on Google+Tweet about this on TwitterShare on LinkedInPin on PinterestShare on TumblrEmail this to someone